Valuation dashboard for Veracyte, Inc. (VCYT) with P/E 32.72, P/B 2.63, EV/EBITDA 26.17 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Analysis Summary
Veracyte, Inc. reported revenue of $517.1M in the most recent fiscal year, growing at a 5-year CAGR of 34.5%.
Trailing-twelve-month margins: gross margin 72.1%, operating margin 17.0%, net margin 20.4%.
At the current price of $47.67, VCYT trades at a P/E of 32.72 and an ROE of 8.64%. Market capitalisation stands at $3.8B.
Balance sheet quality for VCYT: current ratio of 8.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 32.72 |
| Price / Book | 2.63 |
| EV / EBITDA | 26.17 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $36.70 |
| vs Current Price | -23.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| VCYT | Veracyte, Inc. | $3.7B | 32.72 | 2.63 | 8.6% |
| SRRK | Scholar Rock Holding Corporation | $5.6B | 24.09 | -160.2% | |
| APLS | Apellis Pharmaceuticals, Inc. | $5.3B | 38.71 | 12.46 | 6.0% |
| FOLD | Amicus Therapeutics, Inc. | $4.5B | 16.33 | -2.3% | |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.8B | 70.83 | 8.99 | 13.7% |
| LEGN | Legend Biotech Corporation | $3.4B | 2.82 | ||
| IDYA | IDEAYA Biosciences, Inc. | $3.6B | 2.87 | -11.1% | |
| IRON | Disc Medicine, Inc. | $2.4B | 3.87 | -28.7% |
Price
| Price | $47.67 |
| Market Cap | $3.8B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 8.64% |
| Return on Invested Capital | 6.70% |
| Return on Assets | 7.70% |
| Gross Margin | 72.09% |
| Operating Margin | 17.03% |
| Net Margin | 20.37% |
Related companies: ADPT · IDYA · IRON · KNSA · LEGN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of VCYT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks